Memorial Sloan Kettering Cancer Center
New York, New York
Dr. Jhaveri is an Assistant Attending Physician and serves as the Section Head for the Endocrine Therapy Research Program and as the Clinical Director for the Early Drug Development Service at MSKCC. She is an Assistant Professor at Weill Cornell Medicine in NYC. After earning her medical degree and training in nuclear medicine from the University of Mumbai, she completed Internal Medicine residency from Icahn School of Medicine at Mount Sinai (Morningside/West) Program in NY and Medical Oncology/Hematology fellowship at MSKCC. From 7/2012-5/2015, she served as an Assistant Professor at New York University and as an Attending Physician at the Langone Medical Center and at Bellevue Hospital.
Dr. Jhaveri’s primary research interests focus on the development of improved therapies for patients with breast cancer, with a focus on conducting novel clinical trials integrated with translational biomarker work. She has led the development of many targeted therapies including and not limited to PI3K/Akt inhibitors, FGFR inhibitors, ERBB2 inhibitors, oral SERD’s, Antibody-drug conjugates, amongst others.
Dr. Jhaveri currently serves as a member of the ASCO/TAPUR Molecular Tumor Board and as a member of the expert panel for ASCO’s guideline on use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage breast cancer. She is a member of the Alliance Breast Committee and serves as the Co-Chair for the Endocrine Resistance working group within the Translational Breast Cancer Research Consortium. Her work has been presented at annual scientific meetings and she has been published widely in many reputable journals.
Abbive (Individual(s) Involved: Self; Clinical Condition: Breast Cancer): Advisory Board, Consultant, Grant/Research Support, Research Paid to Institution; ADC Therapeutics (Individual(s) Involved: Self; Clinical Condition: Breast Cancer): Grant/Research Support, Research Paid to Institution; Astra Zeneca (Individual(s) Involved: Self): Advisory Board, Consultant, Other Financial or Material Support, Research Support to the Institution; Biotheranostics (Individual(s) Involved: Self): Advisory Board, Consultant; Blueprint Medicines Corporation (Individual(s) Involved: Self): Consultant; Bristol Myer Squibb (Individual(s) Involved: Self; Clinical Condition: Breast Cancer): Advisory Board, Consultant; Clovis Oncology (Individual(s) Involved: Self; Clinical Condition: Breast Cancer): Grant/Research Support, Research Paid to Institution; Debio Pharmaceuticals (Individual(s) Involved: Self): Other Financial or Material Support; Genentech (Individual(s) Involved: Self): Advisory Board, Consultant, Other Financial or Material Support, Research Support to the Institution; Immunomedics (Individual(s) Involved: Self; Clinical Condition: Breast Cancer): Grant/Research Support, Research Paid to Institution; Jounce Therapeutics (Individual(s) Involved: Self; Clinical Condition: Breast Cancer): Advisory Board, Consultant; Lilly Pharmaceuticals (Individual(s) Involved: Self): Advisory Board, Consultant, Other Financial or Material Support, Research Support to the Institution; Merck (Individual(s) Involved: Self): Other Financial or Material Support, Research Support to the Institution; Novartis (Individual(s) Involved: Self): Advisory Board, Consultant, Grant/Research Support, Research Paid to Institution; Novita Pharmaceuticals (Individual(s) Involved: Self): Other Financial or Material Support, Research Support to the Institution; Pfizer (Individual(s) Involved: Self): Consultant; PUMA Biotechnology (Individual(s) Involved: Self): Other Financial or Material Support, Research Support to the Institution; Seattle Genetics (Individual(s) Involved: Self; Clinical Condition: Breast Cancer): Advisory Board, Consultant; Sun Pharma (Individual(s) Involved: Self; Clinical Condition: Breast Cancer): Advisory Board, Consultant; Taiho Oncology (Individual(s) Involved: Self; Clinical Condition: Breast Cancer): Advisory Board, Consultant; Zymeworks (Individual(s) Involved: Self): Other Financial or Material Support, Research Support to the Institution
Wednesday, April 27, 2022
2:35 PM – 3:25 PM
Thursday, April 28, 2022
9:00 AM – 10:10 AM
Thursday, April 28, 2022
9:25 AM – 9:45 AM
Thursday, April 28, 2022
9:45 AM – 10:10 AM
Wednesday, September 21, 2022
9:10 AM – 10:15 AM
Wednesday, September 21, 2022
9:35 AM – 9:55 AM
Wednesday, September 21, 2022
9:55 AM – 10:15 AM